Shares of Agios Pharmaceuticals (AGIO) fell more than 12% on Friday after the U.S. FDA issued a three-month review extension for its marketing application seeking a label expansion for its lead product, Pyrukynd In July, the regulator granted priority review for
Shares of Agios Pharmaceuticals (AGIO) fell more than 12% on Friday after the U.S.
FDA issued a three-month review extension for its marketing application seeking a label expansion for its lead product, Pyrukynd
In July, the regulator granted priority review for
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
